LRH1 enhances cell resistance to chemotherapy by transcriptionally activating MDC1 expression and attenuating DNA damage in human breast cancer

Liver receptor homolog-1 (LRH1) has been shown to promote tumor proliferation and development. However, the functions of LRH1 in mediating cancer cells chemoresistance are still not clear. Here, we found LRH1 levels were significantly elevated in primary breast cancer tissues in patients who developed early recurrence. Similarly, adriamycin (ADR)-resistant breast cancer cell lines also exerted high LRH1 expression. Indeed, overexpression of LRH1 attenuated cytotoxicity of chemotherapeutic drugs ADR and cisplatin (DDP) in breast cancer cells in vitro and in nude mice tumor model. Comet and BrdU assays showed overexpression of LRH1 blocked breast cancer cells DNA damage by chemotherapeutic drug, whereas depletion of LRH1 enhanced DNA damage. Remarkably, knockdown of LRH1 decreased the levels and foci of DNA damage marker γH2AX induced by ADR and DDP. Furthermore, plasmid end-joining assay indicated that knockdown of LRH1 significantly decreased non-homologous end-joining (NHEJ)-mediated double-strand break (DSB) repair efficiencies. Afterwards, we provided evidences that LRH1 promoted MDC1 transcription by directly activating MDC1 promoter and therefore increased γH2AX levels. Importantly, a LRH1-binding site mapped between −1812 and −1804 bp of the proximal MDC1 promoter was identified. Moreover, LRH1 and MDC1 mRNA levels were positively correlated in recurrent breast cancer samples. These results implied LRH1 enhanced breast cancer cell chemoresistance by upregulating MDC1 and attenuating DNA damage. Additionally, we elucidated the coactivator NCOA3 acted synergistically with LRH1 to promote MDC1 expression and chemoresistance. Altogether, LRH1-MDC1 signaling might be considered as a novel molecular target for designing novel therapeutic regimen in chemotherapy resistance breast cancer.

[1]  Stephen J. Elledge,et al.  MDC1 is a mediator of the mammalian DNA damage checkpoint , 2003, Nature.

[2]  Peter Bouwman,et al.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance , 2012, Nature Reviews Cancer.

[3]  Wei Zheng,et al.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 , 2010, Nature Genetics.

[4]  L. Argaman,et al.  The DNA Damage Response Mediator MDC1 Directly Interacts with the Anaphase-promoting Complex/Cyclosome* , 2007, Journal of Biological Chemistry.

[5]  S. Ashwell,et al.  DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy , 2008, Clinical Cancer Research.

[6]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[7]  Robert A. Baldock,et al.  ATM Localization and Heterochromatin Repair Depend on Direct Interaction of the 53BP1-BRCT2 Domain with γH2AX , 2015, Cell reports.

[8]  Ji Liao,et al.  Structural mechanism of the phosphorylation-dependent dimerization of the MDC1 forkhead-associated domain , 2012, Nucleic acids research.

[9]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[10]  S. Bianco,et al.  LRH-1 controls proliferation in breast tumor cells by regulating CDKN1A gene expression , 2014, Oncogene.

[11]  E. Thompson,et al.  The orphan nuclear receptor LRH-1 promotes breast cancer motility and invasion. , 2010, Endocrine-related cancer.

[12]  Meng-Lay Lin,et al.  LRH-1 drives colon cancer cell growth by repressing the expression of the CDKN1A gene in a p53-dependent manner , 2015, Nucleic acids research.

[13]  J. Bartek,et al.  MDC1 is required for the intra-S-phase DNA damage checkpoint , 2003, Nature.

[14]  T. Maudelonde,et al.  The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene , 2005, Oncogene.

[15]  R. Bonner,et al.  Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks , 2003, Nature Cell Biology.

[16]  Jie Xu,et al.  Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells , 2012, Autophagy.

[17]  M. Yaffe,et al.  MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks , 2008, Cell.

[18]  D. Mittelman,et al.  DNA end joining becomes less efficient and more error-prone during cellular senescence. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Stephen P. Jackson,et al.  Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage , 2005, Nature.

[20]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[21]  D. Xing,et al.  Drp1, Mff, Fis1, and MiD51 are coordinated to mediate mitochondrial fission during UV irradiation‐induced apoptosis , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  A. Vincent-Salomon,et al.  Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients , 2016, EMBO molecular medicine.

[23]  Mylène Brunelle,et al.  LRH-1 governs vital transcriptional programs in endocrine-sensitive and -resistant breast cancer cells. , 2014, Cancer research.

[24]  D. Stocco,et al.  Liver receptor homologue-1 is expressed in human steroidogenic tissues and activates transcription of genes encoding steroidogenic enzymes. , 2002, The Journal of endocrinology.

[25]  S. Smerdon,et al.  The molecular basis of ATM-dependent dimerization of the Mdc1 DNA damage checkpoint mediator , 2012, Nucleic acids research.

[26]  Zhaojian Liu,et al.  MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition , 2015, Tumor Biology.

[27]  Yuriy L Orlov,et al.  The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. , 2010, Cell stem cell.

[28]  Johan Auwerx,et al.  LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. , 2004, Trends in cell biology.

[29]  D. Xing,et al.  The Essential Role of Drp1 and Its Regulation by S-Nitrosylation of Parkin in Dopaminergic Neurodegeneration: Implications for Parkinson's Disease. , 2016, Antioxidants & redox signaling.

[30]  S. Kliewer,et al.  LRH-1 and PTF1-L coregulate an exocrine pancreas-specific transcriptional network for digestive function. , 2011, Genes & development.

[31]  G. Bourque,et al.  The PGC-1α/ERRα Axis Represses One-Carbon Metabolism and Promotes Sensitivity to Anti-folate Therapy in Breast Cancer. , 2016, Cell reports.

[32]  Stephen P. Fox,et al.  Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells , 2013, Nucleic acids research.

[33]  Jiri Bartek,et al.  Mdc1 couples DNA double‐strand break recognition by Nbs1 with its H2AX‐dependent chromatin retention , 2004, The EMBO journal.

[34]  Simak Ali,et al.  The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cells , 2011, Breast Cancer Research and Treatment.

[35]  Z. Zou,et al.  FOXM1 promotes invasion and migration of colorectal cancer cells partially dependent on HSPA5 transactivation , 2016, Oncotarget.

[36]  Tao Zhang,et al.  Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. , 2016, Biochemical and biophysical research communications.

[37]  H. Yao,et al.  Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy* , 2015, The Journal of Biological Chemistry.

[38]  T. Misteli,et al.  Activation of DNA damage response signaling by condensed chromatin. , 2014, Cell reports.

[39]  Wei Xu,et al.  Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3 , 2016, Cell Death & Disease.

[40]  Barbara Burwinkel,et al.  Association of NCOA3 Polymorphisms with Breast Cancer Risk , 2005, Clinical Cancer Research.

[41]  E. Simpson,et al.  Therapeutic potential of Liver Receptor Homolog-1 modulators , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  J. Auwerx,et al.  Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. , 2004, Molecular cell.

[43]  Jiang Zhu,et al.  Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression , 2016, Cell Death & Disease.

[44]  M. Goldberg,et al.  The cellular response to DNA damage: a focus on MDC1 and its interacting proteins. , 2010, Nucleus.

[45]  S. Kliewer,et al.  Orphan Nuclear Receptor LRH-1 Is Required To Maintain Oct4 Expression at the Epiblast Stage of Embryonic Development , 2005, Molecular and Cellular Biology.

[46]  Cindy Benod,et al.  Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation , 2011, Proceedings of the National Academy of Sciences.

[47]  Ian A. Cree,et al.  Molecular chess? Hallmarks of anti-cancer drug resistance , 2017, BMC Cancer.

[48]  J. Auwerx,et al.  Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.